Type I and Type II Errors in Genomics Studies

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-22

Key Takeaways

• Type I errors (false positives) occur when a null hypothesis is wrongly rejected, leading to the reporting of spurious genetic associations or differentially expressed genes that cannot be replicated. Control is achieved through multiple testing corrections like Bonferroni or False Discovery Rate (FDR) methods, and by using independent replication cohorts.
• Type II errors (false negatives) occur when a true association is missed and the null hypothesis is incorrectly retained, resulting in the abandonment of potentially important disease-causing variants or therapeutic targets. Increasing sample size and enhancing statistical power are primary strategies to mitigate Type II errors.
• Multiple testing correction is critical in genomics due to the vast number of simultaneous hypotheses tested (e.g., millions of SNPs in GWAS, tens of thousands of genes in transcriptomics). Family-wise error rate (FWER) control methods like Bonferroni are conservative, while False Discovery Rate (FDR) control methods (e.g., Benjamini-Hochberg) offer greater power by accepting a controlled proportion of false positives.
• Statistical power, the probability of correctly detecting a true effect, is influenced by effect size, sample size, significance threshold, and measurement variability. Small effect sizes common in genomics necessitate large sample sizes, often determined via power calculations performed before data collection to avoid underpowered studies.
• Genomics research workflows should adopt a stage-dependent error control strategy: permissive FDR control in discovery (prioritizing Type II error reduction), conservative FWER control in validation (prioritizing Type I error reduction), and a balanced approach with adequate power in independent replication.
• Transparent reporting of the number of tests performed, the specific multiple testing correction method used, the significance threshold, and the power calculations is essential for reproducibility and for assessing the reliability of genomic findings.

Quick Answer

• Type I errors are false positives where a null hypothesis is wrongly rejected, while Type II errors are false negatives where a true effect is missed.
• Control Type I error in genomics by applying multiple testing corrections such as Bonferroni or false discovery rate methods before declaring significance.
• Increasing sample size and effect size improves statistical power to detect true associations, but no single design eliminates both error types simultaneously.

Understanding Statistical Errors in Genomics Research

Genomics studies generate massive datasets with thousands to millions of simultaneous hypothesis tests. Each test carries the risk of two distinct errors. A Type I error occurs when a researcher concludes that a genetic variant is associated with a trait when no true association exists. A Type II error occurs when a true association is missed and the null hypothesis is incorrectly retained. The balance between these errors shapes every genome-wide association study, differential expression analysis, and variant calling pipeline.

The fundamental challenge in genomics is that the cost of each error type differs by context. In diagnostic applications, a false positive may lead to unnecessary clinical intervention. In drug target discovery, a false negative may abandon a promising therapeutic candidate. Researchers must decide which error matters more for their specific question and design their analysis accordingly.

At a Glance: Error Types and Their Consequences

The Multiple Testing Problem in High Dimensional Data

Genomics experiments routinely test hundreds of thousands of hypotheses simultaneously. A typical genome-wide association study examines millions of single nucleotide polymorphisms. A transcriptomics experiment measures expression levels for tens of thousands of genes. Each individual test carries a nominal Type I error rate, often set at 5 percent. When thousands of tests are performed, the probability that at least one false positive appears approaches certainty.

The National Library of Medicine Research Methods Resources provides access to authoritative biomedical texts that explain the mathematical foundations of multiple testing. The core issue is that the family-wise error rate, the probability of making at least one Type I error across all tests, grows with the number of comparisons. If a researcher tests 10,000 hypotheses at a 5 percent significance level, the expected number of false positives is 500 even when no true effects exist.

Family-Wise Error Rate Control

The Bonferroni correction is the most conservative approach. It divides the desired significance level by the number of tests performed. For 1 million tests at a 5 percent overall error rate, each individual test must achieve a p value below 0.00000005. This approach guarantees that the probability of any false positive remains below the chosen threshold.

The cost of Bonferroni correction is substantial. It assumes that all tests are independent, which is rarely true in genomics. Linkage disequilibrium among nearby genetic variants creates correlated tests. The correction becomes overly conservative, increasing Type II errors and causing researchers to miss genuine associations.

False Discovery Rate Control

The false discovery rate approach, introduced by Benjamini and Hochberg, controls the expected proportion of false positives among all rejected hypotheses. This method is less conservative than family-wise error rate control and is widely used in genomics. It allows researchers to accept a small proportion of false discoveries in exchange for greater power to detect true associations.

The choice between family-wise error rate and false discovery rate control depends on the research question. If the goal is to identify a single causal variant with high confidence, family-wise error rate control is appropriate. If the goal is to generate a list of candidate genes for further investigation, false discovery rate control provides a better balance between Type I and Type II errors.

Statistical Power and Sample Size Determination

Statistical power is the probability of correctly rejecting a false null hypothesis, which is the complement of the Type II error rate. A study with 80 percent power has a 20 percent chance of missing a true effect. Power depends on four factors: the effect size, the sample size, the significance threshold, and the variability of the measurements.

In genomics, effect sizes are often small. A single genetic variant may explain only a small fraction of the heritability of a complex trait. Detecting such effects requires large sample sizes. The National Institutes of Health Grants and Funding resources describe how grant reviewers evaluate the statistical justification for proposed sample sizes. A study that lacks adequate power to detect its primary hypothesis is unlikely to receive funding.

Calculating Required Sample Size

Sample size calculations require an estimate of the expected effect size, the acceptable Type I error rate, and the desired power. For a genome-wide association study, the significance threshold is set by the multiple testing correction. The effect size is estimated from prior studies or biological knowledge. The power is typically set at 80 percent or higher.

Researchers must be realistic about effect sizes. If the true effect is smaller than the estimate used in the calculation, the study will be underpowered. This leads to a high Type II error rate and a failure to detect true associations. The result is a null finding that does not distinguish between a true absence of effect and a study that was too small to detect it.

Power Tradeoffs in Study Design

Increasing sample size is the most reliable way to reduce Type II errors. However, sample size is often constrained by cost, patient availability, or ethical considerations. Researchers must balance the desire for high power against the practical limits of their study.

Alternative strategies to increase power include reducing measurement noise through better laboratory protocols, using more precise phenotyping, or combining data across multiple cohorts. Meta-analysis of independent studies can achieve the sample size needed to detect small effects. The EQUATOR Network provides reporting guidelines that help researchers document their power calculations and design decisions transparently.

Practical Workflow for Managing Error Rates

A systematic approach to managing Type I and Type II errors begins before data collection and continues through analysis and reporting.

Step 1: Define the Research Question and Error Priorities

Decide whether the study prioritizes avoiding false positives or avoiding false negatives. A confirmatory study that aims to validate a specific hypothesis should use a conservative significance threshold. An exploratory study that aims to generate hypotheses should use a more permissive threshold with false discovery rate control.

Step 2: Conduct a Power Analysis

Estimate the expected effect size from the literature or pilot data. Determine the significance threshold that will be used after multiple testing correction. Calculate the sample size needed to achieve 80 percent power. Document these calculations in the study protocol.

Step 3: Pre-Specify the Analysis Plan

Decide in advance which statistical tests will be performed and which multiple testing correction will be applied. Pre-specification prevents the temptation to adjust the analysis after seeing the results. The Committee on Publication Ethics Core Practices emphasize the importance of transparent reporting of analysis decisions.

Step 4: Apply Multiple Testing Correction

After the analysis is complete, apply the chosen correction method. For genome-wide studies, the false discovery rate approach is often appropriate. For studies with a small number of pre-specified hypotheses, the Bonferroni correction may be sufficient.

Step 5: Validate Findings in Independent Cohorts

A finding that survives multiple testing correction in one cohort may still be a false positive. Replication in an independent cohort provides strong evidence that the association is real. The replication study should be adequately powered to detect the effect size observed in the initial study.

Step 6: Report the Results Transparently

Report the number of tests performed, the correction method used, the number of significant findings, and the power of the study. The EQUATOR Network provides reporting guidelines for genetic association studies and other research designs. Transparent reporting allows other researchers to assess the reliability of the findings.

Options and Tradeoffs in Error Control

Conservative vs. Permissive Thresholds

The choice of significance threshold is a trade-off between Type I and Type II errors. A more conservative threshold reduces false positives but increases false negatives. A more permissive threshold does the opposite. The optimal threshold depends on the cost of each error type in the specific research context.

In drug development, a false positive may lead to a costly clinical trial of an ineffective drug. A false negative may abandon a drug that could have worked. The relative costs of these errors determine the appropriate threshold.

Correction Methods

The Bonferroni correction is simple and controls the family-wise error rate strictly. The Benjamini-Hochberg procedure controls the false discovery rate and is more powerful. Other methods, such as the Holm-Bonferroni method, provide intermediate levels of control. The choice of method should be based on the research question and the correlation structure of the data.

Bayesian Approaches

Bayesian methods provide an alternative framework for hypothesis testing. Instead of p values, Bayesian analysis produces posterior probabilities that a hypothesis is true given the data and prior information. These methods can incorporate prior biological knowledge and provide a more nuanced view of evidence. However, they require specification of prior distributions, which can be subjective.

Observations and Measurements in Error Control

Recording Analysis Decisions

Every analysis decision should be recorded in a laboratory notebook or electronic data management system. The record should include the number of tests performed, the correction method used, the significance threshold, and the power calculation. This documentation is essential for reproducibility and for responding to reviewer questions.

Monitoring False Discovery Rates

In large-scale studies, researchers can estimate the false discovery rate from the distribution of p values. A flat distribution of p values near 1 suggests that most tests are null. A peak of small p values suggests that some tests are true positives. These observations can help researchers assess whether their results are reliable.

Quality Control Metrics

Quality control metrics in genomics, such as genotype call rates, sample contamination, and batch effects, can influence error rates. Poor quality data increases variability and reduces power. It can also introduce systematic biases that create false associations. The NIH Data Management and Sharing Policy describes expectations for data quality and documentation.

Common Failure Patterns in Error Management

Ignoring Multiple Testing

The most common failure is to analyze thousands of tests without any correction. This produces a large number of false positives that cannot be replicated. Reviewers and editors will reject such studies.

Overcorrection

Applying the Bonferroni correction to correlated tests is overly conservative. This produces a high Type II error rate and misses true associations. Researchers should use methods that account for the correlation structure of the data.

Underpowered Studies

A study with too few samples to detect the expected effect size is a waste of resources. The study will produce null results that are uninformative. The power analysis should be performed before data collection, not after.

P-Hacking

P-hacking is the practice of analyzing data in multiple ways until a significant result is found. This practice inflates the Type I error rate and produces unreplicable findings. Pre-specification of the analysis plan prevents p-hacking.

Selective Reporting

Reporting only the significant results and omitting the non-significant results distorts the scientific record. The Committee on Publication Ethics Core Practices require that researchers report all results, including those that are not significant.

Reproducibility and Data Management

Reproducibility requires that the analysis can be repeated with the same data and the same methods. This requires careful data management and documentation. The NIH Data Management and Sharing Policy describes expectations for data sharing and management in NIH-funded research.

Data Documentation

The data should be documented with metadata that describes the variables, the measurement methods, and the data quality. The analysis code should be version-controlled and documented. The analysis should be run in a reproducible environment.

Data Sharing

Sharing data allows other researchers to verify the results and to perform additional analyses. The NIH Data Management and Sharing Policy requires that data be shared in a timely manner. Data sharing also allows for meta-analysis, which can increase power and reduce Type II errors.

Researcher Identity

The ORCID for Researchers provides a persistent identifier for researchers. This identifier links researchers to their publications and data. It ensures that researchers receive credit for their work and that the scientific record is accurate.

Limitations and Interpretation Boundaries

Statistical Significance Is Not Biological Significance

A statistically significant result does not mean that the effect is biologically meaningful. A large sample size can produce a statistically significant result for a tiny effect that has no practical importance. Researchers should report the effect size and its confidence interval, beyond the p value.

The Null Hypothesis Is a Simplification

The null hypothesis of no association is a simplification. In genomics, many variants have small effects that are difficult to detect. A non-significant result does not prove that there is no effect. It only indicates that the study did not have enough power to detect it.

Replication is Essential

A single study, even with a low p value, is not sufficient to establish a true association. Replication in independent cohorts is essential. The replication should be performed with the same rigor as the initial study.

The File Drawer Problem

The file drawer problem refers to the tendency to publish only significant results. This distorts the scientific record and makes it difficult to assess the true evidence. Researchers should publish non-significant results and make their data available.

Professional Escalation Criteria

When to Consult a Biostatistician

A biostatistician should be consulted when the study design is complex, when the data have a complex correlation structure, or when the analysis requires advanced methods. A biostatistician can help with power calculations, multiple testing corrections, and the interpretation of results.

When to Seek Peer Review

Peer review is essential for the quality of the research. The Committee on Publication Ethics Core Practices describe the responsibilities of authors and reviewers. A colleague with statistical expertise should review the analysis plan before data collection and the results before submission.

When to Report a Concern

If a researcher suspects that a colleague has engaged in p-hacking or selective reporting, they should report the concern. The Committee on Publication Ethics Core Practices provide guidance on handling allegations of misconduct.

A Decision Framework for Error Control in Multi-Stage Genomics Studies

The existing discussion of Type I and Type II errors treats each analysis as a single isolated decision. In practice, genomics research unfolds across multiple stages, from discovery screening to targeted validation to replication. Each stage presents a different balance between false positives and false negatives, and the optimal error control strategy changes as the research progresses. A fixed significance threshold applied uniformly across all stages will either flood the discovery stage with noise or starve the validation stage of candidate signals. This section provides a practical decision framework for allocating error control across the stages of a genomics study, with concrete records, troubleshooting methods, and escalation criteria.

The Stage-Dependent Nature of Error Costs

The cost of a Type I error is not constant throughout a research program. In the discovery stage, a false positive is an inconvenience. It consumes validation resources and adds noise to the candidate list, but it does not by itself derail the research. The cost of a Type II error in discovery is much higher. A missed true association is gone forever from that dataset, and the researcher may never return to it. The asymmetry of these costs argues for a permissive threshold in discovery, with false discovery rate control instead of family-wise error rate control.

In the validation stage, the balance shifts. The candidate list is smaller, and each candidate receives deeper scrutiny. A false positive that survives validation is expensive because it moves forward to replication or functional studies. The cost of a Type II error in validation is lower because the candidate remains in the literature and can be picked up by other groups. This asymmetry argues for a more conservative threshold in validation.

In the replication stage, the cost of a Type I error is highest. A replicated false positive becomes a published association that other researchers will build upon. The cost of a Type II error in replication is also meaningful, because a true association that fails to replicate may be abandoned. The replication stage requires a threshold that balances both errors, with the balance determined by the prior probability that the candidate is real.

A Three-Stage Decision Framework

The framework below assigns a distinct error-control strategy to each stage of a genomics study. The stages are defined by their purpose, not by the specific technology or platform.

Stage 1: Discovery Screening

The purpose of the discovery stage is to generate a candidate list that is enriched for true associations. The goal is not to identify the final set of associations but to avoid missing any that might be real. The primary error to control is the Type II error, because a missed candidate cannot be recovered later.

The recommended strategy is false discovery rate control at a permissive level, typically 5 to 10 percent. The Benjamini-Hochberg procedure is appropriate for this stage because it does not require independence among tests and it scales to millions of comparisons. The output of this stage is a candidate list, not a set of conclusions. The candidate list should be recorded with the false discovery rate threshold used and the number of candidates that passed.

The key record for this stage is the total number of tests performed, the number of candidates selected, and the estimated false discovery rate. The National Library of Medicine Research Methods Resources provides background on the mathematical properties of false discovery rate control that are relevant to this stage.

Stage 2: Targeted Validation

The purpose of the validation stage is to test the candidate list with independent data or independent methods. The candidate list is smaller, typically tens to hundreds of candidates, so the multiple testing burden is lower. The primary error is the Type I error, because the candidates have already been selected and the cost of a false positive is now higher.

The recommended strategy is family-wise error rate control with a Bonferroni or Holm correction applied to the number of candidates tested. If the validation uses a different measurement platform, such as genotyping arrays for a sequencing discovery, the validation should be designed to detect the effect size observed in discovery with at least 80 percent power. The validation stage should be pre-specified, with the candidate list locked before the validation data are examined.

The key record for this stage is the validation sample size, the effect size used for the power calculation, and the number of candidates that survived the correction. A common failure is to apply the same genome-wide threshold to the validation stage, which is overly conservative and increases the Type II error rate.

Stage 3: Independent Replication

The purpose of the replication stage is to confirm the validated candidates in an independent cohort. The candidate list is now small, typically fewer than 20 candidates. The primary error is the Type I error, because a replicated false positive will enter the literature as a confirmed association. The recommended strategy is a fixed significance threshold, typically 0.05, applied to each candidate individually, with the understanding that the replication is testing a small number of pre-specified hypotheses.

The replication stage requires a power calculation based on the effect size observed in the validation stage. The replication cohort must be large enough to detect that effect size with 80 percent power. If the replication cohort is smaller than required, the study should be reported as underpowered for replication, and the results should be interpreted with that limitation.

The key record for this stage is the replication cohort size, the observed effect size in the validation stage, and the power calculation. The EQUATOR Network provides reporting guidelines that specify how replication results should be documented.

A Decision Table for Threshold Selection

The table below summarizes the recommended error-control strategy for each stage. The thresholds are starting points, not universal rules. The researcher should adjust them based on the specific costs of Type I and Type II errors in their research context.

The table is a decision aid, not a substitute for statistical judgment. The researcher should document the rationale for the chosen threshold in the study protocol.

Records and Measurements for the Framework

The framework requires a record system that tracks the error-control decisions across stages. The following records should be maintained for each stage.

Stage-Specific Analysis Log

The analysis log should record the date of the analysis, the software version, the number of tests performed, the correction method, the threshold applied, and the number of candidates selected. The log should be updated when the analysis is rerun with different parameters. The NIH Data Management and Sharing Policy describes expectations for documenting analysis decisions in NIH-funded research.

Candidate Tracking Table

The candidate tracking table lists each candidate from the discovery stage and its status in the validation and replication stages. The table should include the candidate identifier, the discovery p value, the validation p value, the replication p value, and the final status. The table should be updated as each stage is completed.

Power Calculation Records

The power calculation records should include the effect size estimate, the significance threshold, the desired power, and the calculated sample size for each stage. The records should be updated when the effect size estimate changes based on new data.

Troubleshooting the Framework

The framework fails in predictable ways. The following troubleshooting method addresses the most common failure patterns.

Failure Pattern 1: Discovery Produces No Candidates

If the discovery stage produces no candidates at the chosen false discovery rate threshold, the first check is the power of the discovery study. A study with low power will produce no candidates even when true associations exist. The power calculation should be reviewed to confirm that the sample size was adequate for the expected effect size. If the power was adequate, the next check is the quality of the data. Batch effects, genotyping errors, and phenotype misclassification can all reduce the signal. The National Library of Medicine Research Methods Resources provide guidance on quality control in genomics studies.

If the data quality is acceptable and the power was adequate, the researcher should consider whether the false discovery rate threshold was too strict. A threshold of 5 percent may be too conservative for a discovery screen. The threshold can be relaxed to 10 percent, but the researcher should document the change and the rationale.

Failure Pattern 2: Validation Fails for All Candidates

If no candidates survive the validation stage, the first check is the validation method. A different genotyping platform or a different measurement method can produce different results. The validation should be checked for batch effects and technical artifacts. The second check is the effect size. The validation stage may be underpowered to detect the effect size observed in the discovery stage. The power calculation should be reviewed to confirm that the validation sample size was sufficient.

If the validation method and power are acceptable, the researcher should consider whether the discovery stage produced false positives. A discovery false discovery rate of 10 percent means that 10 percent of the candidates are expected to be false positives. If the candidate list was small, the absolute number of false positives may be small, but the proportion of candidates that fail validation may be high.

Failure Pattern 3: Replication Fails for Validated Candidates

The replication stage is the most common point of failure. A candidate that survives discovery and validation may still fail to replicate. The first check is the replication cohort. The replication cohort must be independent of the discovery and validation cohorts. If the replication cohort overlaps with the discovery cohort, the replication is not independent and the result is not a true replication.

The second check is the effect size. The replication cohort may be underpowered to detect the effect size observed in the validation stage. The power calculation should be reviewed. The third check is the phenotype. The replication cohort may use a different phenotype definition, which can change the effect size.

If the replication cohort is independent and adequately powered, the failure to replicate may indicate that the original finding was a false positive. The researcher should report the failed replication and the original finding with the replication result.

Escalation Criteria for the Framework

The framework includes criteria for escalating to a biostatistician or a statistical reviewer. The Committee on Publication Ethics Core Practices describe the responsibilities of authors to seek appropriate statistical review.

Escalate When the False Discovery Rate Is Unstable

The false discovery rate estimate is unstable when the number of candidates is small. If the discovery stage produces fewer than 10 candidates, the false discovery rate estimate is not reliable. A biostatistician should be consulted to determine whether the false discovery rate control is appropriate or whether a different approach is needed.

Escalate When the Effect Size Is Uncertain

The power calculations in the framework depend on the effect size estimate. If the effect size estimate is based on a small pilot study or on a single prior report, the estimate is uncertain. A biostatistician should be consulted to evaluate the sensitivity of the power calculations to the effect size uncertainty.

Escalate When the Data Have a Complex Correlation Structure

The false discovery rate control in the discovery stage assumes that the tests are independent or that the correlation structure is accounted for. If the data have a complex correlation structure, such as related individuals in a family-based study or a population structure with admixture, the false discovery rate control may be invalid. A biostatistician should be consulted to evaluate the correlation structure and to recommend an appropriate correction.

The Role of Pre-Specification in the Framework

The framework is most effective when the stage thresholds are pre-specified before the data are collected. Pre-specification prevents the researcher from adjusting the thresholds after seeing the results, which inflates the Type I error rate. The pre-specified thresholds should be documented in the study protocol and in the analysis plan.

The EQUATOR Network provides reporting guidelines that require the pre-specification of the analysis plan. The Committee on Publication Ethics Core Practices require that the analysis plan be reported transparently.

The Role of the Framework in Grant Applications

The framework is useful for grant applications because it demonstrates that the researcher has considered the error trade-offs across the stages of the study. The National Institutes of Health Grants and Funding resources describe how grant reviewers evaluate the statistical justification for proposed studies. A grant application that includes a stage-specific error-control plan is more likely to be reviewed favorably than one that applies a single threshold to the entire study.

The grant application should include the power calculations for each stage, the thresholds for each stage, and the rationale for the thresholds. The application should also describe the record system that will be used to track the error-control decisions.

The Framework in the Context of Data Sharing

The framework produces a record of the error-control decisions that is useful for data sharing. The NIH Data Management and Sharing Policy requires that data be shared with sufficient documentation for other researchers to understand the analysis. The stage-specific records provide this documentation.

The data sharing plan should include the stage logs, the candidate tracking table, and the power calculation records. The plan should describe how the data will be shared and how the analysis code will be made available.

The Framework and Researcher Identity

The framework produces a record of the analysis decisions that is linked to the researcher. The ORCID for Researchers provides a persistent identifier that links the researcher to their publications and data. The stage logs and the candidate tracking table should be linked to the researcher's ORCID record to ensure that the researcher receives credit for the analysis decisions.

Limitations of the Framework

The framework is a decision aid, not a substitute for statistical judgment. The thresholds in the table are starting points, and the researcher should adjust them based on the specific research context. The framework does not eliminate the trade-off between Type I and Type II errors. It makes the trade-off explicit and provides a structure for managing it across the stages of the study.

The framework assumes that the stages are sequential and that the candidate list is locked at each stage. If the researcher revisits the discovery stage after the validation stage, the framework is no longer valid. The researcher should document any deviations from the framework and the rationale for the deviations.

The framework does not address the biological interpretation of the results. A statistically significant association is not necessarily biologically meaningful. The researcher should interpret the results in the context of the biological knowledge and the effect sizes.

The Framework in Practice

The framework is applied in the following sequence. The researcher defines the research question and the error priorities. The researcher conducts the power analysis for the discovery stage and the discovery threshold. The researcher collects the discovery data and applies the false discovery rate control. The researcher records the candidates in the candidate tracking table. The researcher conducts the validation stage with the Bonferroni correction. The researcher records the validation results. The researcher conducts the replication stage with the fixed threshold. The researcher records the replication results. The researcher reports the results with the stage-specific thresholds and the power calculations.

The framework is a practical tool for managing the trade-off between Type I and Type II errors in genomics studies. It provides a structure for the analysis decisions and a record for the decisions. The framework is not a substitute for statistical expertise, and the researcher should consult a biostatistician when the framework is uncertain.

Frequently Asked Questions

What is the difference between a Type I and a Type II error?

A Type I error is a false positive, where a true null hypothesis is rejected. A Type II error is a false negative, where a false null hypothesis is not rejected. In genomics, a Type I error is a spurious association, and a Type II error is a missed true association.

How does multiple testing correction affect Type I and Type II errors?

Multiple testing correction reduces the Type I error rate by making the significance threshold more stringent. This increases the Type II error rate because it becomes harder to reject the null hypothesis. The choice of correction method balances these two errors.

What is the false discovery rate?

The false discovery rate is the expected proportion of false positives among all rejected hypotheses. It is controlled by the Benjamini-Hochberg method. It is less conservative than the Bonferroni correction and provides more power.

How can I increase the power of my study?

Power can be increased by increasing the sample size, reducing measurement noise, or increasing the effect size. A power analysis should be performed before data collection to determine the required sample size.

What is the difference between a p value and a false discovery rate?

A p value is the probability of observing the data if the null hypothesis is true. The false discovery rate is the expected proportion of false positives among the rejected hypotheses. The false discovery rate is a more useful measure in multiple testing.

What is the role of replication in controlling errors?

Replication in an independent cohort provides strong evidence that a finding is not a false positive. A finding that is replicated is more likely to be a true association. Replication is an essential part of the scientific process.

How should I report the results of a multiple testing analysis?

Report the number of tests, the correction method, the significance threshold, and the number of significant findings. Report the effect sizes and confidence intervals. Follow the reporting guidelines from the EQUATOR Network.

What should I do if my results are not significant?

A non-significant result is a valid result. It should be reported. It may indicate that the effect is small or that the study is underpowered. The result should be interpreted in the context of the power of the study.

Related Bioinformatics Guides

• Genomic Data Analysis Tools: A Comparative Guide for Researchers
• Metagenomic Contamination Control: Best Practices for Clean Data
• Benchmarking Atlas-Level Data Integration in Single-Cell Genomics: Methods and Best Practices
• Data Stewardship vs Data Governance: What's the Difference?
• Single-Cell Genomics: From Concept to Application

Related Clinical & Scientific Guides

• A Practical Guide to Detecting Antimicrobial Resistance Genes in Shotgun Metagenomic Data
• Computational Immunology: Modeling the Immune System
• How to Set Hard Filters for Germline Variant Calling: A Practical Guide to GATK Best Practices

References and Further Reading

• Research Methods Resources. National Library of Medicine.
• EQUATOR Network. EQUATOR Network.
• Core Practices. Committee on Publication Ethics.
• NIH Grants and Funding. National Institutes of Health.
• ORCID for Researchers. ORCID.
• Data Management and Sharing Policy. National Institutes of Health.
• NCBI Data Resources. National Center for Biotechnology Information.
• EMBL-EBI Training. European Bioinformatics Institute.
• Adenylosuccinate lyase deficiency.. Journal of inherited metabolic disease, 2015.
• [[Metabolic myopathies].](https://pubmed.ncbi.nlm.nih.gov/23897158). Revista de neurologia, 2013.
• An assessment of the performance of the probabilistic genotyping software EuroForMix: Trends in likelihood ratios and analysis of Type I & II errors.. Forensic science international. Genetics, 2019.

This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.